Retina Group of New England is proud to participate in the most cutting-edge research for vitreo-retinal diseases in Connecticut and Rhode Island. Our extensive work has attributed to some of the latest developments in retinal disease treatment. Based in New London, our research center conducts clinical trials for the treatment of diseases such as Wet Macular Degeneration, Dry Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusions.
| Neovascular (Wet) Macular Degeneration | Treatment | Treatment Status | Vision Criteria |
| DAYLIGHT | Intravitreal KSI-301 | Treatment naive | 20/32-20/320 |
| BELVEDRE | Susvimo | Previously treated with Eylea or Avastin | Better than 20/400 |
| ATMOSPHERE | Gene Therapy | Previously treated | 20/20-20-200 |
| SANDOZ | Intravitreal Biosimilar | Treatment naive | 20/40-20/320 |
| VILLA | Commercial Susvimo | Post SUSVIMO implant | observational |
| Dry Macular Degeneration | Treatment | Treatment Status | Vision Criteria |
| ALEXION | ALXN2040 Oral | Treatment naive, no Exud AMD | 20/25-20/800 |
| Diabetic Retinopathy | Treatment | Treatment Status | Vision Criteria |
| GLOW | Intravitreal KSI-301 | Treatment naive | Better than 20/50 |
| Retinal Vein Occlusion | Treatment | Treatment Status | Vision Criteria |
We are constantly investigating new treatment options. To participate in enrolling clinical trials, or for more information on the newest developments in retinal disease treatment/management, please contact our study coordinator, Emma at (860) 444-1292.
Clinical trials we are currently participating in but that are closed for enrollment:
DERBY – Intravitreal Pegcetacoplan for Geographic Atrophy
GALE – Intravitreal Pegcetacoplan for Geographic Atrophy – Open Label Extension of Oaks and Derby
RHONE X – Intravitreal Faricimab for Diabetic Macular Edema – Open Label Extension of Rhine
AVONELLE X– Intravitreal Faricimab for Neovascular Macular Degeneration – Open Label Extension of Tenaya
BALATON – Intravitreal Faricimab for Branch Retinal Vein Occlusion
COMINO – Intravitreal Faricimab for Central Retinal Vein Occlusion
PORTAL – Port Delivery System with Lucentis for Neovascular Macular Degeneration – Open Label Extension of Archway
PAGODA – Port Delivery System with Lucentis for Diabetic Macular Edema
GLIMMER – Intravitreal KSI-301 for Diabetic Macular Edema
BEACON – Intravitreal KSI-301 for Retinal Vein Occlusion
PULSAR – Intravitreal high dose Eylea for Neovascular Macular Degeneration
PHOTON – Intravitreal high dose Eylea for Diabetic Macular Edema
NGM – Intravitreal NGM601 for Diabetic Macular Edema
AMGEN – Intravitreal biosimilar for Neovascular Macular Degeneration
Clinical trials we previously participated in:
OAKS – Intravitreal Pegcetacoplan for Geographic Atrophy
TENAYA – Intravitreal Faricimab for Neovascular Macular Degeneration
PAVILLION – Ranibizumab for Non Proliferative Diabetic Retinopathy
ARCHER– Intravitreal ANX007 for Geographic Atrophy
CANBERRA – Oral Cannabinoids for Diabetic Retinopathy
CANDELA – High dose Eylea for Neovascular Macular Degeneration
TOPAZ – Suprachoroidal Steroid for Retinal Vein Occlusion
MYLAN– Intravitreal Aflibercept biosimilar for Diabetic Retinopathy
RHINE – Intravitreal Faricimab for Diabetic Retinopathy
ARCHWAY – Port Delivery system Lucentis for Neovascular Macular Degeneration
GRAYBUG – Intravitreal Depot of Sunitinub Malate for Neovascular Macular Degeneration
PANDA 2 – Intravitreal Conversept for Exudative Macular Degeneration
SCORE2 LTE – Standard of care for Retinal Vein Occlusion
PANORAMA – Intravitreal aflibercept vs Sham for Mild-Moderate NPDR
PANDA – Intravitreal Conversept vs. Aflibercept for Neovascular Macular Degeneration
TLC Study – Intravitreal ProDex for Retinal Vein Occlusion with Edema 2017-present (TLC)
Study of Oral Emixustat Hydrochloride for Proliferative Diabetic Retinopathy 2017 (ACUCELA)
MAKO Study – Topical Squalamine Lactate for Neovascular (wet) Age-Related Macular Degeneration 2016-2017 (OHR)
ONYX Study – Intravitreal REGN910-3 for Neovascular (wet) Age-Related Macular Degeneration 2016-2017 (Regeneron)
RUBY Study – Intravitreal REGN910-3 for Diabetic Macular Edema 2016-2017 (Regeneron)
FILLY Study – Intravitreal APL-2 for Dry Age-Related Macular Degeneration with Geographic Atrophy 2015-2018 (Appelis)
Next study phase starting in summer of 2018
Panorama Study – Intravitreal Eylea to prevent progression of Diabetic Retinopathy 2015-present (Regeneron)
CAPELLA Study – Intravitreal REGN2176-3 for Neovascular (wet) Age-Related Macular Degeneration 2015-2017 (Regeneron)
APEX Study – Oral X82 for Neovascular (wet) Age-Related Macular Degeneration 2015-2018 (Tyrogenex)
Del Mar Study – Intravitreal Luminate for Diabetic Macular Edema 2015-2017 (Allegro)
Phase III study is coming
HAWK study – Intravitreal brolucizumab for Neovascular (wet) Age-Related Macular Degeneration 2015-2018 (Alcon)
Study results went to FDA for approval
DRCR Protocol U – Compared anti-VEGF and intravitreal corticosteroids+anti-VEGF for Diabetic Macular Edema 2015-2016
DRCR Protocol V – Compared treatments for Diabetic Macular Edema with good vision 2014-2017
DRCR Protocol T – Compared effectiveness of Avastin, Lucentis and Eylea for Diabetic Macular Edema 2012-2015
DRCR Protocol S – Compared Panretinal Photocoagulation and Lucentis for PDR 2012-2017
Based on study results Lucentis was FDA approved for Diabetic Retinopathy in 2017
SCORE2 Study and SCORE@ LTE – Compares intravitreal Eylea and Avastin for Central Retinal Vein Occlusion
1 year treatment and 4 years follow up 2014-present (EMMES)
SPECTRI Study – Intravitreal Lampalizumab for Dry Age-Related Macular Degeneration with Geographic Atrophy 2014-2018 (Genentech)
Eclipse and OPH1006 Studies – Intravitreal Fovista for Neovascular (wet) Age-Related Macular Degeneration 2013-2017 (Ophthotech)
Study of oral X82 for Neovascular (wet) Age-Related Macular Degeneration 2012-2015(tyrogenex)
VISTA Study – Intravitreal Eylea for Diabetic Macular Edema 2011-2014 (Regeneron)
Based on study results Eylea was FDA approved for Diabetic Macular Edema in 2014
SHORE Study – Intravitreal Lucentis for Edema secondary to Retinal Vein Occlusion 2011-2012 (Genentech)
COPERNICUS Study – Intravitreal Eylea for Central Retinal Vein Occlusion 2009-2012 (Regeneron)
Based on study results Eylea was FDA approved edema secondary to Central Retinal Vein Occlusion in 2012
RIDE Study – Intravitreal Lucentis for Diabetic Macular Edema 2007-2012 (Genentech)
Based on study results Lucentis was FDA approved for Diabetic Macular Edema in 2012
CRUISE Study – Intravitreal Lucentis for Central Retinal Vein Occlusion 2008-2009 (Genentech)
Based on study results Lucentis was approved by FDA for Retinal Vein Occlusion in 2010
BRAVO Study – Intravitreal Lucentis for Branch Retinal Vein Occlusion 2008-2009 (Genentech)
Based on study results Lucentis was approved by FDA for Retinal Vein Occlusion in 2010
HARBOR Study – Comparing regular and high dose of Intravitreal Lucentis for Neovascular (wet) Age-Related Macular Degeneration 2009-2012 (Genentech)
VIEW 1 Study – Intravitreal Eylea for Neovascular (wet) Age-Related Macular Degeneration 2008-2010 (Regeneron)
Eyelea was approved by FDA for Neovascular (wet) Age-Related Macular Degeneration based on this study results in 2011
FAME Study – Intravitreal insert of Fluocinolone acetonide 2006-2010 (Alimera)
Sustain release insert of FA was approved by FDA in 2014 for Diabetic Macular Edema
SAILOR Study – Intravitreal Lucentis 2005-2006 (Genentech)
The only research site in South Eastern Connecticut that participated in this final study prior to FDA approval of Lucentis for Neovascular (wet) Age-Related Macular Degeneration in June of 2006